Filter by Year:
Press Releases
-
Sep 05, 2023
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Aug 31, 2023
Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML
-
Aug 08, 2023
Foghorn Therapeutics Announces Chief Medical Officer Succession
-
Aug 04, 2023
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
-
Jun 28, 2023
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma
-
Jun 07, 2023
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
-
Jun 05, 2023
Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
-
May 08, 2023
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
-
Apr 25, 2023
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
-
Apr 24, 2023
Foghorn Therapeutics Provides an Update on FHD-609
Displaying 1 - 10 of 15